403
Sorry!!
Error! We're sorry, but the page you were
looking for doesn't exist.
2025 Research | United States Diabetes Monitoring, Treatment And Drug Delivery Market To Reach $79 Billion By 2031
(MENAFN- GlobeNewsWire - Nasdaq) Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The "Diabetes Monitoring, Treatment and Drug Delivery Market Size, Share & Trends Analysis | United States | 2025-2031 | MedSuite | Includes: Insulin & GLP-1, Continuous Glucose Monitoring and 7 more" report has been added to ResearchAndMarkets.com's offering.
The United States diabetes monitoring, treatment, and drug delivery market is set to achieve significant growth in the coming years. With a notable value of $48 billion in 2024, the market is forecasted to expand at a compound annual growth rate (CAGR) of 7.3%, surging ahead to a projected value of $79 billion by 2031. This upward trajectory is influenced by the escalating prevalence of diabetes and technological advancements poised to refine diabetes care.
Segment Analysis
Findings from a recent market analysis have shown that during 2024, the insulin and GLP-1 receptor agonist sector surfaced as the largest and most swiftly expanding segment, capturing the lion's share of the market. Growth drivers for this segment include the increase in type 2 diabetes and obesity cases, a burgeoning demand for cutting-edge treatment alternatives, and progressive therapies that tackle both conditions concurrently.
Competitive Landscape
Within this developing landscape, enterprises such as Novo Nordisk, Eli Lilly, and Dexcom stand out as top competitors, with each bringing unique contributions to the market. Novo Nordisk leads with its robust offering in the insulin and GLP-1 space, Eli Lilly shines with its premium insulin options, and Dexcom dominates the continuous glucose monitoring market segment.
Advancements and Trends
Research highlights the rising demand for smart insulin pens, which is attributable to their advanced features that support dosing accuracy and enhanced compliance. Additionally, continuous improvements in glucose monitoring and insulin delivery systems, anchored by digital health solutions, are projected to propel the market forward.
Market Forecast and Analysis
Expert analysis provided in the report furnishes in-depth insights into market trends up to 2031 and includes historical data dating back to 2021. The market evaluation encapsulates a wide array of data, from unit sales to average selling prices, while also covering qualitative aspects such as the impact of COVID-19, competitive analyses, and an overview of disease implications.
Segregation and Focus
The report meticulously segments the market into various categories, such as personal and professional blood glucose meters, test strips, lancets, insulin pens, syringes, and pumps, as well as CGM and FGM systems, mapping out the specifics of each niche to provide a comprehensive market overview.
As the United States diabetes market progresses, the implications of these findings are poised to play a defining role for stakeholders, policymakers, and healthcare providers engaged in diabetes care. For further information on the market or to engage in discussions regarding the implications of these findings, interested parties are invited to consult with industry experts.
A selection of companies mentioned in this report includes, but is not limited to:
The United States diabetes monitoring, treatment, and drug delivery market is set to achieve significant growth in the coming years. With a notable value of $48 billion in 2024, the market is forecasted to expand at a compound annual growth rate (CAGR) of 7.3%, surging ahead to a projected value of $79 billion by 2031. This upward trajectory is influenced by the escalating prevalence of diabetes and technological advancements poised to refine diabetes care.
Segment Analysis
Findings from a recent market analysis have shown that during 2024, the insulin and GLP-1 receptor agonist sector surfaced as the largest and most swiftly expanding segment, capturing the lion's share of the market. Growth drivers for this segment include the increase in type 2 diabetes and obesity cases, a burgeoning demand for cutting-edge treatment alternatives, and progressive therapies that tackle both conditions concurrently.
Competitive Landscape
Within this developing landscape, enterprises such as Novo Nordisk, Eli Lilly, and Dexcom stand out as top competitors, with each bringing unique contributions to the market. Novo Nordisk leads with its robust offering in the insulin and GLP-1 space, Eli Lilly shines with its premium insulin options, and Dexcom dominates the continuous glucose monitoring market segment.
Advancements and Trends
Research highlights the rising demand for smart insulin pens, which is attributable to their advanced features that support dosing accuracy and enhanced compliance. Additionally, continuous improvements in glucose monitoring and insulin delivery systems, anchored by digital health solutions, are projected to propel the market forward.
Market Forecast and Analysis
Expert analysis provided in the report furnishes in-depth insights into market trends up to 2031 and includes historical data dating back to 2021. The market evaluation encapsulates a wide array of data, from unit sales to average selling prices, while also covering qualitative aspects such as the impact of COVID-19, competitive analyses, and an overview of disease implications.
Segregation and Focus
The report meticulously segments the market into various categories, such as personal and professional blood glucose meters, test strips, lancets, insulin pens, syringes, and pumps, as well as CGM and FGM systems, mapping out the specifics of each niche to provide a comprehensive market overview.
As the United States diabetes market progresses, the implications of these findings are poised to play a defining role for stakeholders, policymakers, and healthcare providers engaged in diabetes care. For further information on the market or to engage in discussions regarding the implications of these findings, interested parties are invited to consult with industry experts.
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott
- Home Aide Diagnostics
- ACON Laboratories
- iHealth Labs
- AgaMatrix
- Infopia
- Allison Medical
- Insulet
- ApexBio
- Intuity Medical
- Arcadia Group
- i-SENS
- ARKRAY
- LifeScan
- Ascensia
- Livongo Health
- AstraZeneca
- McKesson
- B. Braun
- Medlin
- BD
- Medtronic
- Bionime
- Nova Biomedical
- Biosense Medical Devices
- Novo Nordisk
- Boehringer Ingelheim
- Oak Tree Health
- Companion Medical
- Omnis Health
- CanAm
- One Drop
- CVS
- Owen Mumford
- DarioHealth
- Perrigo
- Eli Lilly
- Pharma Supply
- Excel International
- Philosys
- Fifty 50 Medical
- Platinum Equity
- ForaCare
- Playtex
- Genesis Health Technologies
- Prodigy
- Gluco Perfect
- Retractable Technologies
- Hikma Pharmaceuticals
- Roche
- Sanofi
- Terumo
- SD Biosensor
- Trivia Health
- Senseonics
- U.S. Diagnostics
- Simple Diagnostics
- UltiMed
- Smart Meter
- Unilife Medical Solutions
- Smiths Medical
- Valeritas
- Specialty Medical Supplies
- Vertex Diagnostics
- STAT Medical Devices
- Viatris
- Tandem
- Walmart
- Teva Pharmaceuticals
- Ypsomed
- Telcare
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Most popular stories
More Story
Comments
No comment